

S2 Table. Univariate and multivariate analysis for clinical outcomes

Characteristic (comparison vs. reference)	Local control				Locoregional control				Recurrence-free survival				Overall survival			
	Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate	
	HR	p-	HR	p-	HR	p-	HR	p-	HR	p-	HR	p-	HR	p-	HR	p-value
	(95% CI)	value	(95% CI)	value	(95% CI)	value	(95% CI)	value	(95% CI)	value	(95% CI)	value	(95% CI)	value	(95% CI)	
Brachytherapy technology (IGBT vs CBT)	0.672 (1.487- 0.161)	0.587	0.454 (0.100- 2.058)	0.306	0.704 (0.304- 1.626)	0.410	0.421 (0.154- 1.151)	0.092	0.896 (0.419-1.915)	0.777	0.711 (0.320- 1.579)	0.402	0.672 (0.225- 2.013)	0.478	0.617 (0.206- 1.848)	0.388
Age (continuous)	0.977 (0.927- 1.030)	0.391	-	-	0.986 (0.956- 1.017)	0.376	-	-	0.982 (0.955-1.010)	0.212	-	-	0.999 0.962- 1.038	0.972	-	-
Parametrial invasion (yes vs. no)	2.067 (0.253- 16.86)	0.498	-	-	1.435 (0.487- 4.230)	0.512	-	-	1.655 (0.571-4.793)	0.354	-	-	4.673 0.599- 36.46	0.141	-	-
Pelvic lymph node metastasis (yes vs. no)	0.844 (0.201- 3.547)	0.817	-	-	2.565 (0.871- 7.550)	0.087	2.815 (0.905- 8.757)	0.074	2.459 (0.930-6.503)	0.070	-	-	1.960 0.545- 7.041	0.303	-	-
Paraaortic lymph node metastasis (yes vs. no)	1.587 (0.320- 7.877)	0.572	-	-	0.954 (0.324- 2.804)	0.931	-	-	1.399 (0.564-3.471)	0.469	-	-	1.590 0.439- 5.757	0.480	-	-
Pelvic organ invasion (yes vs. no)	2.359 (0.290- 19.22)	0.422	-	-	1.542 (0.361- 6.588)	0.559	-	-	1.306 (0.309-5.519)	0.717	-	-	1.090 0.142- 8.349	0.934	-	-
Distant metastasis (yes vs. no)	5.655 (0.690- 46.34)	0.106	-	-	4.624 (1.079- 19.81)	0.039	4.120 (0.900- 18.86)	0.068	4.875 (1.128-21.07)	0.034	4.738 (1.057- 21.24)	0.042	4.613 0.590- 36.09	0.145	-	-

Initial tumor size (continuous)	1.230 (0.826- 1.833)	0.309	-	-	1.268 (1.016- 1.581)	0.035	1.288 (1.017- 1.632)	0.036	1.222 (0.994-1.503)	0.057	1.195 (0.960- 1.487)	0.112	1.461 1.085- 1.967	0.013	1.459 (1.090- 1.952)	0.011
EBRT pelvic dose (50.4 Gy vs. circa 45 Gy)	-	-	-	-	1.500 (0.509- 4.415)	0.462	-	-	1.253 (0.433-3.627)	0.678	-	-	1.567 0.434- 5.663	0.493	-	-
EBRT lymph node boost (yes vs. no)	0.797 (0.189- 3.362)	0.757	-	-	1.775 (0.656- 4.802)	0.258	-	-	1.757 (0.707-4.364)	0.225	-	-	1.929 0.536- 6.946	0.315	-	-
EBRT parametrial boost (yes vs. no)	2.259 (0.565- 9.036)	0.249	-	-	0.959 (0.394- 2.331)	0.926	-	-	0.748 (0.316-1.770)	0.509	-	-	0.932 0.292- 2.975	0.906	-	-
EBRT cervical tumor boost (yes vs. no)	1.744 (0.214- 14.21)	0.603	-	-	2.029 (0.601- 6.853)	0.255	-	-	1.862 (0.560-6.188)	0.310	-	-	0.959 0.125- 7.338	0.968	-	-
Concurrent cisplatin regimen (tri-weekly vs. weekly)	3.859 (0.767- 19.42)	0.101	-	-	2.521 (0.850- 7.480)	0.096	3.423 (0.859- 13.64)	0.081	1.930 0.663- 5.615	0.228	-	-	2.316 0.511- 10.50	0.276	-	-
Lymph node dissection (yes vs. no)	11.00 (2.542- 47.61)	0.001	13.24 (2.989- 58.62)	0.001	3.440 (1.163- 10.17)	0.026	3.247 (0.914- 11.54)	0.069	2.681 0.924- 7.783	0.070	3.172 (0.998- 10.09)	0.051	2.818 0.622- 12.76	0.179	-	-

3D-CRT, three-dimensional conformal radiation therapy; CBT, conventional brachytherapy; CI, confidence interval; EBRT, external beam radiation therapy; HR, hazard ratio; IGBT, image-guided brachytherapy.